Skip to content
value.today

Hepalife Technologies Inc.

Total raised
$38 M
10 rounds on record
Latest round
$3 M
Feb 2017
First round on record
May 2010
Today
Private
No later event on record

Funding rounds

10 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Hepalife Technologies Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2017$3 MNo. 10$2 to $10 million

Hepalife Technologies Inc.: Raise no. 10, Feb 2017

Investors in this round

8 investors had bought by the notice of Mar 13, 2017: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$196,180
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brad Barton · Executive Officer · Chief Operating Officer
  • Brian Posner · Executive Officer · Chief Financial Officer, Treasurer and Secretary
  • David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer
  • Pellegrino Pionati · Executive Officer · Chief Strategy and Marketing Officer
  • Gary Restani · Director · Director
  • Jeffrey Sklar · Director · Director
  • Jerome Zeldis · Director · Director
  • Joseph Leone · Director · Director
  • Mark Wagner · Director · Director
  • Winston Kung · Director · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cova Capital Partners, LLC (CRD 109761) · Syosset, New YorkSold in CA, NJ, NY, PA
  • Rodman & Renshaw, LLC (CRD 281264) · broker-dealer H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, NJ

Remarks in the notice

  • On fees: “$161,980 was paid to Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC. $34,200 was paid to Cova Capital Partners, LLC.”

Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 13, 2017. Read the notice at the SEC.

equitySEC
May 2014$2 MIssued in a merger or acquisition$2 to $10 million

Hepalife Technologies Inc.: Private sale, May 2014

Investors in this round

43 investors had bought by the notice of May 15, 2014: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $7 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Brian Posner · Executive Officer · Chief Financial Officer, Treasurer and Secretary of the Issuer
  • David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer
  • David Stefansky · Director
  • Jeffrey Sklar · Director
  • Jerome Zeldis · Director
  • Joseph Leone · Director
  • Kenneth Pearsen · Director
  • Perry Karsen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The former stockholders of Choice Therapeutics, Inc. may receive in aggregate up to an additional $5 million in shares of the Common Stock of Alliqua, Inc., in an earnout payment 37 months following the closing.”

Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D, newest notice filed May 15, 2014. Read the notice at the SEC.

equitySEC
Apr 2014$15 MNo. 9$10 to $50 million

Hepalife Technologies Inc.: Raise no. 9, Apr 2014

Investors in this round

18 investors had bought by the notice of Apr 28, 2014: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$598,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Brian Posner · Executive Officer · Chief Financial Officer, Treasurer and Secretary of the Issuer
  • David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer
  • David Stefansky · Director
  • Jeffrey Sklar · Director
  • Jerome Zeldis · Director
  • Joseph Leone · Director
  • Kenneth Pearsen · Director
  • Perry Karsen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Summer Street Research Partners (CRD 127412) · New York, New YorkSold in CT, MA, MD, NJ, NY, PA

Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 28, 2014. Read the notice at the SEC.

equity, optionsSEC
Nov 2013$7 MNo. 8$2 to $10 million

Hepalife Technologies Inc.: Raise no. 8, Nov 2013

Investors in this round

12 investors had bought by the notice of Nov 25, 2013: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$490,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Brian Posner · Executive Officer · Chief Financial Officer of the Issuer
  • David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer
  • David Stefansky · Director
  • Jeffrey Sklar · Director
  • Jerome Zeldis · Director
  • Joseph Leone · Director
  • Kenneth Londoner · Director
  • Kenneth Pearsen · Director
  • Richard Rosenblum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Summer Street Research Partners (CRD 127412) · New York, New YorkSold in CA, MA, MD, NY, PA

Remarks in the notice

  • On fees: “The Issuer also issued a five year warrant to purchase 136,585 shares of common stock at an exercise price of $5.69 per share to the placement agent as consideration for serving as the placement agent.”

Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 25, 2013. Read the notice at the SEC.

equity, optionsSEC
Nov 2013$6 MNo. 7$2 to $10 million

Hepalife Technologies Inc.: Raise no. 7, Nov 2013

Investors in this round

1 investor had bought by the notice of Nov 25, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Brian Posner · Executive Officer · Chief Financial Officer of the Issuer
  • David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer
  • David Stefansky · Director
  • Jeffrey Sklar · Director
  • Jerome Zeldis · Director
  • Joseph Leone · Director
  • Kenneth Londoner · Director
  • Kenneth Pearsen · Director
  • Richard Rosenblum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 25, 2013. Read the notice at the SEC.

equity, optionsSEC
Oct 2013$1 MNo. 6Under $2 million

Hepalife Technologies Inc.: Raise no. 6, Oct 2013

Investors in this round

1 investor had bought by the notice of Nov 18, 2013: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$70,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • Brian Posner · Executive Officer · Chief Financial Officer of the Issuer
  • David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer
  • David Stefansky · Director
  • Jeffrey Sklar · Director
  • Jerome Zeldis · Director
  • Joseph Leone · Director
  • Kenneth Londoner · Director
  • Kenneth Pearsen · Director
  • Richard Rosenblum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Summer Street Research Partners (CRD 127412) · New York, New YorkSold in MA

Remarks in the notice

  • On fees: “Issuer also issued five year warrants to purchase (i) 388,889 shares of common stock at a $.10 per share exercise price and (ii) 388,889 shares of common stock at an $.11 per share exercise price to the placement agent as consideration for its service.”

Signed by Brian Posner, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 18, 2013. Read the notice at the SEC.

equity, optionsSEC
Jun 2013$2 MNo. 5Under $2 million

Hepalife Technologies Inc.: Raise no. 5, Jun 2013

Investors in this round

30 investors had bought by the notice of Jul 9, 2013: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$62,632
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer
  • Steven Berger · Executive Officer · Chief Financial Officer of the Issuer
  • David Stefansky · Director
  • Jeffrey Sklar · Director
  • Jerome Zeldis · Director
  • Joseph Leone · Director
  • Kenneth Londoner · Director
  • Kenneth Pearsen · Director
  • Richard Rosenblum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Summer Street Research Partners (CRD 127412) · New York, New YorkSold in CA, CO, CT, FL, NJ, NY, PA

Remarks in the notice

  • On fees: “The Issuer also issued a five year warrant to purchase 773,235 shares of common stock at an exercise price of $0.097 per share to the placement agent as consideration for serving as the placement agent.”

Signed by Steven Berger, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 9, 2013. Read the notice at the SEC.

equity, optionsSEC
Apr 2013$1 MNo. 4Under $2 million

Hepalife Technologies Inc.: Raise no. 4, Apr 2013

Investors in this round

26 investors had bought by the notice of Jun 10, 2013: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$99,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • David Johnson · Executive Officer, Director · President, Chief Executive Officer and Director of the Issuer
  • Steven Berger · Executive Officer · Chief Financial Officer of the Issuer
  • David Stefansky · Director
  • Jeffrey Sklar · Director
  • Jerome Zeldis · Director
  • Joseph Leone · Director
  • Kenneth Londoner · Director
  • Kenneth Pearsen · Director
  • Richard Rosenblum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New YorkSold in AR, CA, FL, IA, IL, KY, NC, NJ, OH, OK, PA, TX

Remarks in the notice

  • On fees: “The Issuer also issued a five year warrant to purchase 1,222,222 shares of common stock at an exercise price of $0.097 per share to the placement agent as consideration for serving as the placement agent.”

Signed by Steven Berger, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 10, 2013. Read the notice at the SEC.

equity, optionsSEC
Feb 2012$1 MNo. 3Under $2 million

Hepalife Technologies Inc.: Raise no. 3, Feb 2012

Investors in this round

12 investors had bought by the notice of Mar 1, 2012: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$55,475
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Florida

People named in the notice

  • Richard Rosenblum · Executive Officer, Director · President and Director of the Issuer
  • Steven C. Berger · Executive Officer · Chief Financial Officer of the Issuer
  • David Stefansky · Director · Chairman of the Issuer
  • Jeffrey M. Sklar · Director
  • Joseph M. Leone · Director
  • Joseph Sierchio · Director
  • Kenneth M. Pearsen · Director
  • Michael M. Goldberg · Director
  • Nochum M. Stein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Palladium Capital Advisors, LLC (CRD 129400) · New York, New YorkSold in FL, NJ, NY, and outside the US

Remarks in the notice

  • On fees: “The Issuer also issued a five year warrant to purchase 1,109,500 shares of common stock at an exercise price of $0.069 per share to the placement agent as consideration for serving as the placement agent.”
  • On the amounts: “The Issuer issued 21,000,000 shares of common stock and five year warrants to purchase an aggregate of 10,500,000 shares of common stock to the investor in exchange for aggregate consideration of $1,050,000.”

Signed by Steven Berger, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 1, 2012. Read the notice at the SEC.

equity, optionsSEC
Mar 2011$1 MNo. 2Under $2 million

Hepalife Technologies Inc.: Raise no. 2, Mar 2011

Investors in this round

1 investor had bought by the notice of Mar 17, 2011: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$154,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Florida

People named in the notice

  • David Stefansky · Executive Officer, Director · Chairman of the Issuer
  • Richard Rosenblum · Executive Officer, Director · President and Director of the Issuer
  • Steven C. Berger · Executive Officer · Chief Financial Officer of the Issuer
  • Jeffrey M. Sklar · Director
  • Joseph M. Leone · Director
  • Joseph Sierchio · Director
  • Kenneth M. Pearsen · Director
  • Michael M. Goldberg · Director
  • Nochum M. Stein · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Palladium Capital Advisors, LLC (CRD 129400) · New York, New YorkSold in FL

Remarks in the notice

  • On fees: “The Issuer issued 437,500 shares of common stock and a five year warrant to purchase 312,500 shares of common stock to the placement agent as consideration for serving as the placement agent.”
  • On the amounts: “The Issuer issued 6,250,000 shares of common stock and a five year warrant to purchase 6,250,000 shares of common stock to the investor in exchange for aggregate consideration of $1,000,000.”

Signed by Richard Rosenblum, President and Director of the Issuer. Source: SEC Form D, newest notice filed Mar 17, 2011. Read the notice at the SEC.

equity, optionsSEC
May 2010$1 MNo. 1Under $2 million

Hepalife Technologies Inc.: Raise no. 1, May 2010

Investors in this round

15 investors had bought by the notice of May 25, 2010: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $3 M offered; $1 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$114,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Florida

People named in the notice

  • David Stefansky · Executive Officer, Director · Chairman and Director of the Issuer
  • Richard Rosenblum · Executive Officer · President of the Issuer
  • Steven C. Berger · Executive Officer · Chief Financial Officer, Treasurer and Secretary of the Issuer
  • Joseph C. Sierchio · Director · Director of the Issuer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Palladium Capital Advisors, LLC (CRD 129400) · New York, New YorkSold in FL, NY, TX

Remarks in the notice

  • On fees: “Palladium Capital Advisors, LLC received a cash fee of $114,000, plus Series E Warrants to purchase 456,000 shares of common stock, Series F Warrants to purchase 456,000 shares of common stock, and 2,000,000 shares of common stock.”

Signed by Steven C. Berger, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed May 25, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Hepalife Technologies Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2017).

    SEC Form D · Mar 2017

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2017

That is all the official record says: Hepalife Technologies Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Hepalife Technologies Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 10 rounds above had up to 30 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Hepalife Technologies Inc.
NameRoleNamed in
Brad BartonChief Operating OfficerMar 2017
Brian PosnerChief Financial Officer, Treasurer and SecretaryMar 2017
David JohnsonPresident, Chief Executive Officer and Director of the IssuerMar 2017
Pellegrino PionatiChief Strategy and Marketing OfficerMar 2017
Steven BergerChief Financial Officer of the IssuerJul 2013
Richard RosenblumPresident and Director of the IssuerMar 2012
Steven C. BergerChief Financial Officer of the IssuerMar 2012
David StefanskyChairman of the IssuerMar 2011
David JohnsonPresident, Chief Executive Officer and Director of the IssuerMar 2017
Gary RestaniDirectorMar 2017
Jeffrey SklarDirectorMar 2017
Jerome ZeldisDirectorMar 2017
Joseph LeoneDirectorMar 2017
Mark WagnerDirectorMar 2017
Winston KungDirectorMar 2017
David StefanskyDirectorMay 2014
Kenneth PearsenDirectorMay 2014
Perry KarsenDirectorMay 2014
Kenneth LondonerDirectorNov 2013
Richard RosenblumDirectorNov 2013
Jeffrey M. SklarDirectorMar 2012
Joseph M. LeoneDirectorMar 2012
Joseph SierchioDirectorMar 2012
Kenneth M. PearsenDirectorMar 2012
Michael M. GoldbergDirectorMar 2012
Nochum M. SteinDirectorMar 2012
Joseph C. SierchioDirector of the IssuerMay 2010